Description

Tabituximab barzuxetan (exclude Y90) is a radioimmunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan shows antineoplastic activity. Tabituximab barzuxetan can be used for synovial sarcoma research[1].–Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Anne-Laure Giraudet , et al. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646. -CASNumber-1612758-88-9-MolecularWeight-N/A-Compound Purity–SMILES-[Tabituximab barzuxetan]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Wnt-Isoform–Pathway-Stem Cell/Wnt-MCE Product type-ADC Related